Results 291 to 300 of about 4,193,206 (400)

Extracellular matrix in the trabecular meshwork: intraocular pressure regulation and dysregulation in glaucoma.

open access: yesExperimental Eye Research, 2015
Janice A. Vranka   +3 more
semanticscholar   +1 more source

Low‐Cost New Glaucoma Drainage Device in Indonesia: One Year Follow‐Up of 252 Subjects

open access: yesClinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background To evaluate the early efficacy and safety of a new polymethyl methacrylate 200 mm2 non‐valved glaucoma drainage device (GDD) designed for Indonesian use over a 12 month period. Methods This was a prospective study following subjects with various forms of refractory glaucoma aged ≥ 7 years old followed for 12 months. The subjects had
Virna Dwi Oktariana Asrory   +1 more
wiley   +1 more source

Comparative Effects of Laryngeal Mask Airway and Endotracheal Tube Insertion on Intraocular Pressure in Children

open access: bronze, 1992
Mehernoor F. Watcha   +3 more
openalex   +1 more source

Cataract Surgery in the Small Adult Eye: A Review

open access: yesClinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Modern cataract surgery continues to advance, yet intraocular lens (IOL) based surgery in the small adult eye remains challenging. Thorough preoperative assessment and surgical preparation optimise postoperative outcomes in these cases. Advances in IOL power calculation, including artificial intelligence‐driven formulas, improve accuracy ...
Jonathan E. Moore   +2 more
wiley   +1 more source

Intraocular pressure‐lowering medications and long‐term outcomes of selective laser trabeculoplasty

open access: yesClinical and Experimental Ophthalmology, 2015
D. M. Woo   +3 more
semanticscholar   +1 more source

Safety of an Intravitreal Bevacizumab Biosimilar (MVASI)

open access: yesClinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background Intravitreal bevacizumab has been used off‐label to treat multiple ocular conditions for almost two decades. Reference bevacizumab, Avastin, was discontinued in Australia in 2021. A bevacizumab biosimilar, MVASI, was approved by the Therapeutic Goods Administration for the treatment of metastatic cancer in 2020.
Hanru Wang   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy